TY - JOUR
T1 - A randomized, feasibility trial of an exercise and nutrition-based rehabilitation programme (ENeRgy) in people with cancer
AU - Hall, Charlie C.
AU - Skipworth, Richard J.E.
AU - Blackwood, Honor
AU - Brown, Duncan
AU - Cook, Jane
AU - Diernberger, Katharina
AU - Dixon, Elizabeth
AU - Gibson, Valerie
AU - Graham, Catriona
AU - Hall, Peter
AU - Haraldsdottir, Erna
AU - Hopkinson, Jane
AU - Lloyd, Anna
AU - Maddocks, Matthew
AU - Norris, Lucy
AU - Tuck, Sharon
AU - Fallon, Marie T.
AU - Laird, Barry J.A.
N1 - Funding Information:
The authors would like to thank the following: Southampton Clinical Trials Unit who provided trial oversight, Patient and Public Involvement Representatives—Pamela MacKay and Susan Siegell (Marie Curie Expert Voices); all staff at St Columba's Hospice particularly Tommy Dalgliesh and Gillian Reid (trial volunteers), the Community Palliative Care Team, and Julie Young; Emma Carduff and Anne Finucane (Marie Curie); staff at Marie Curie Hospice Edinburgh. We would like to make a special acknowledgement to Dr Anne C Voss who is a nutritional scientist and provided valuable support throughout the trial. This trial was funded by a grant from Marie Curie and the Chief Scientists Office (Scotland, UK)—MCRGS‐07‐16‐73. Abbott Laboratories provided the oral nutritional supplement (Prosure) used in the trial, free of charge.
Funding Information:
This trial was funded by a grant from Marie Curie and the Chief Scientist Office (Scotland, UK). The oral nutritional supplement was provided free of charge by Abbott Laboratories. The funders and Abbott Laboratories had no involvement in the design, conduct or analysis of the trial. B. L., C. H., M. F., P. H., K. D., E. W., A. L., J. H., and C. G. had access to raw data. The corresponding author had final responsibility for the decision to submit the manuscript for publication.
Funding Information:
The trial was sponsored jointly by the University of Edinburgh and NHS Lothian.
Publisher Copyright:
© 2021 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders.
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
Funding Information:
The authors would like to thank the following: Southampton Clinical Trials Unit who provided trial oversight, Patient and Public Involvement Representatives—Pamela MacKay and Susan Siegell (Marie Curie Expert Voices); all staff at St Columba's Hospice particularly Tommy Dalgliesh and Gillian Reid (trial volunteers), the Community Palliative Care Team, and Julie Young; Emma Carduff and Anne Finucane (Marie Curie); staff at Marie Curie Hospice Edinburgh. We would like to make a special acknowledgement to Dr Anne C Voss who is a nutritional scientist and provided valuable support throughout the trial. This trial was funded by a grant from Marie Curie and the Chief Scientists Office (Scotland, UK)—MCRGS‐07‐16‐73. Abbott Laboratories provided the oral nutritional supplement (Prosure) used in the trial, free of charge.
Funding Information:
This trial was funded by a grant from Marie Curie and the Chief Scientist Office (Scotland, UK). The oral nutritional supplement was provided free of charge by Abbott Laboratories. The funders and Abbott Laboratories had no involvement in the design, conduct or analysis of the trial. B. L., C. H., M. F., P. H., K. D., E. W., A. L., J. H., and C. G. had access to raw data. The corresponding author had final responsibility for the decision to submit the manuscript for publication.
Funding Information:
The trial was sponsored jointly by the University of Edinburgh and NHS Lothian.
Funding Information:
The authors would like to thank the following: Southampton Clinical Trials Unit who provided trial oversight, Patient and Public Involvement Representatives?Pamela MacKay and Susan Siegell (Marie Curie Expert Voices); all staff at St Columba's Hospice particularly Tommy Dalgliesh and Gillian Reid (trial volunteers), the Community Palliative Care Team, and Julie Young; Emma Carduff and Anne Finucane (Marie Curie); staff at Marie Curie Hospice Edinburgh. We would like to make a special acknowledgement to Dr Anne C Voss who is a nutritional scientist and provided valuable support throughout the trial. This trial was funded by a grant from Marie Curie and the Chief Scientists Office (Scotland, UK)?MCRGS-07-16-73. Abbott Laboratories provided the oral nutritional supplement (Prosure) used in the trial, free of charge.
Publisher Copyright:
© 2021 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders.
PY - 2021/12
Y1 - 2021/12
N2 - Background: Despite rehabilitation being increasingly advocated for people living with incurable cancer, there is limited evidence supporting efficacy or component parts. The progressive decline in function and nutritional in this population would support an approach that targets these factors. This trial aimed to assess the feasibility of an exercise and nutrition based rehabilitation programme in people with incurable cancer. Methods: We randomized community dwelling adults with incurable cancer to either a personalized exercise and nutrition based programme (experimental arm) or standard care (control arm) for 8 weeks. Endpoints included feasibility, quality of life, physical activity (step count), and body weight. Qualitative and health economic analyses were also included. Results: Forty-five patients were recruited (23 experimental arm, 22 control arm). There were 26 men (58%), and the median age was 78 years (IQR 69–84). At baseline, the median BMI was 26 kg/m2 (IQR: 22–29), and median weight loss in the previous 6 months was 5% (IQR: −12% to 0%). Adherence to the experimental arm was >80% in 16/21 (76%) patients. There was no statistically significant difference in the following between trial arms: step count − median % change from baseline to endpoint, per trial arm (experimental −18.5% [IQR: −61 to 65], control 5% [IQR: −32 to 50], P = 0.548); weight − median % change from baseline to endpoint, per trial arm (experimental 1%[IQR: −3 to 3], control −0.5% [IQR: −3 to 1], P = 0.184); overall quality of life − median % change from baseline to endpoint, per trial arm (experimental 0% [IQR: −20 to 19], control 0% [IQR: −23 to 33], P = 0.846). Qualitative findings observed themes of capability, opportunity, and motivation amongst patients in the experimental arm. The mean incremental cost of the experimental arm versus control was £-319.51 [CI −7593.53 to 6581.91], suggesting the experimental arm was less costly. Conclusions: An exercise and nutritional rehabilitation intervention is feasible and has potential benefits for people with incurable cancer. A larger trial is now warranted to test the efficacy of this approach.
AB - Background: Despite rehabilitation being increasingly advocated for people living with incurable cancer, there is limited evidence supporting efficacy or component parts. The progressive decline in function and nutritional in this population would support an approach that targets these factors. This trial aimed to assess the feasibility of an exercise and nutrition based rehabilitation programme in people with incurable cancer. Methods: We randomized community dwelling adults with incurable cancer to either a personalized exercise and nutrition based programme (experimental arm) or standard care (control arm) for 8 weeks. Endpoints included feasibility, quality of life, physical activity (step count), and body weight. Qualitative and health economic analyses were also included. Results: Forty-five patients were recruited (23 experimental arm, 22 control arm). There were 26 men (58%), and the median age was 78 years (IQR 69–84). At baseline, the median BMI was 26 kg/m2 (IQR: 22–29), and median weight loss in the previous 6 months was 5% (IQR: −12% to 0%). Adherence to the experimental arm was >80% in 16/21 (76%) patients. There was no statistically significant difference in the following between trial arms: step count − median % change from baseline to endpoint, per trial arm (experimental −18.5% [IQR: −61 to 65], control 5% [IQR: −32 to 50], P = 0.548); weight − median % change from baseline to endpoint, per trial arm (experimental 1%[IQR: −3 to 3], control −0.5% [IQR: −3 to 1], P = 0.184); overall quality of life − median % change from baseline to endpoint, per trial arm (experimental 0% [IQR: −20 to 19], control 0% [IQR: −23 to 33], P = 0.846). Qualitative findings observed themes of capability, opportunity, and motivation amongst patients in the experimental arm. The mean incremental cost of the experimental arm versus control was £-319.51 [CI −7593.53 to 6581.91], suggesting the experimental arm was less costly. Conclusions: An exercise and nutritional rehabilitation intervention is feasible and has potential benefits for people with incurable cancer. A larger trial is now warranted to test the efficacy of this approach.
KW - Cancer
KW - Exercise
KW - Nutrition
KW - Rehabilitation
UR - http://www.scopus.com/inward/record.url?scp=85116344771&partnerID=8YFLogxK
U2 - 10.1002/jcsm.12806
DO - 10.1002/jcsm.12806
M3 - Article
AN - SCOPUS:85116344771
SN - 2190-5991
VL - 12
SP - 2034
EP - 2044
JO - Journal of Cachexia, Sarcopenia and Muscle
JF - Journal of Cachexia, Sarcopenia and Muscle
IS - 6
ER -